Published in Proc Natl Acad Sci U S A on October 10, 2002
The moving parts of the nucleolus. Histochem Cell Biol (2005) 1.81
Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates. J Virol (2004) 1.69
The nucleolus. Cold Spring Harb Perspect Biol (2011) 1.60
Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther (2008) 1.32
Nucleolar trafficking is essential for nuclear export of intronless herpesvirus mRNA. Proc Natl Acad Sci U S A (2006) 1.30
The taming of the cell penetrating domain of the HIV Tat: myths and realities. J Control Release (2006) 1.30
Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. J Virol (2012) 1.12
CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology (2005) 1.10
An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription. Cell Host Microbe (2012) 1.08
Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32. J Virol (2006) 1.06
HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther (2005) 1.05
Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Mol Ther (2009) 1.03
The human I-mfa domain-containing protein, HIC, interacts with cyclin T1 and modulates P-TEFb-dependent transcription. Mol Cell Biol (2003) 0.98
Toward targeting RNA structure: branched peptides as cell-permeable ligands to TAR RNA. ACS Chem Biol (2011) 0.95
Lentiviral transduction of Tar Decoy and CCR5 ribozyme into CD34+ progenitor cells and derivation of HIV-1 resistant T cells and macrophages. AIDS Res Ther (2004) 0.92
Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization. J Acquir Immune Defic Syndr (2009) 0.91
Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1. Mol Ther (2008) 0.91
Nucleolar protein trafficking in response to HIV-1 Tat: rewiring the nucleolus. PLoS One (2012) 0.87
Endogenous MCM7 microRNA cluster as a novel platform to multiplex small interfering and nucleolar RNAs for combinational HIV-1 gene therapy. Hum Gene Ther (2012) 0.86
Optimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance gene. Mol Ther (2014) 0.85
A global sampling approach to designing and reengineering RNA secondary structures. Nucleic Acids Res (2012) 0.84
Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection. Antiviral Res (2011) 0.84
A nucleolar localizing Rev binding element inhibits HIV replication. AIDS Res Ther (2006) 0.84
Didehydro-cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic mice. Curr HIV Res (2015) 0.83
The HIV Tat protein affects processing of ribosomal RNA precursor. BMC Cell Biol (2008) 0.82
Current progress and challenges in HIV gene therapy. Future Virol (2011) 0.82
RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside. Yale J Biol Med (2011) 0.82
Combinatorial RNA-based gene therapy for the treatment of HIV/AIDS. Expert Opin Biol Ther (2013) 0.81
RNA interference approaches for treatment of HIV-1 infection. Genome Med (2015) 0.81
CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape. Viruses (2015) 0.81
Bone Marrow Gene Therapy for HIV/AIDS. Viruses (2015) 0.79
HIV-1 infection causes a down-regulation of genes involved in ribosome biogenesis. PLoS One (2014) 0.77
A dual function TAR Decoy serves as an anti-HIV siRNA delivery vehicle. Virol J (2010) 0.77
Stem cell-based therapies for HIV/AIDS. Adv Drug Deliv Rev (2016) 0.77
Novel in vivo model for the study of human immunodeficiency virus type 1 transcription inhibitors: evaluation of new 6-desfluoroquinolone derivatives. Antimicrob Agents Chemother (2007) 0.76
Inhibition of HIV derived lentiviral production by TAR RNA binding domain of TAT protein. Retrovirology (2005) 0.76
Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy. J Investig Med (2014) 0.76
Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid Assembly. Mol Ther Nucleic Acids (2015) 0.75
Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med (1989) 10.74
Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature (1988) 10.15
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell (1998) 10.14
Ribosome synthesis in Saccharomyces cerevisiae. Annu Rev Genet (1999) 8.72
Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev (1997) 6.88
Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J Biol Chem (1996) 6.78
P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol (2000) 5.64
Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J Biol Chem (1995) 5.31
Reversible phosphorylation of the C-terminal domain of RNA polymerase II. J Biol Chem (1996) 5.15
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev (1997) 5.13
Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol (1991) 5.09
HIV-1 Tat protein promotes formation of more-processive elongation complexes. EMBO J (1991) 4.18
The plurifunctional nucleolus. Nucleic Acids Res (1998) 4.11
Sequence requirements for nucleolar localization of human T cell leukemia virus type I pX protein, which regulates viral RNA processing. Cell (1988) 3.92
Guided tours: from precursor snoRNA to functional snoRNP. Curr Opin Cell Biol (1999) 3.88
Structural and functional characterization of human immunodeficiency virus tat protein. J Virol (1989) 3.57
Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell (1990) 3.36
Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science (2001) 3.02
Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem (1999) 2.81
Subcellular localization of the human immunodeficiency virus trans-acting art gene product. J Virol (1988) 2.64
A rapid method for the construction of synthetic genes using the polymerase chain reaction. Biotechniques (1990) 2.64
TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc Natl Acad Sci U S A (1997) 2.52
Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages. EMBO J (1998) 2.45
In vitro formation of short RNA polymerase II transcripts that terminate within the HIV-1 and HIV-2 promoter-proximal downstream regions. Genes Dev (1989) 2.36
HIV-1 Tat overcomes inefficient transcriptional elongation in vitro. J Mol Biol (1993) 2.12
A novel small nucleolar RNA (U16) is encoded inside a ribosomal protein intron and originates by processing of the pre-mRNA. EMBO J (1993) 2.07
PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo. J Virol (1998) 1.99
The roles of nucleolar structure and function in the subcellular location of the HIV-1 Rev protein. J Cell Sci (1995) 1.93
Effects of a highly basic region of human immunodeficiency virus Tat protein on nucleolar localization. J Virol (1990) 1.89
Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc Natl Acad Sci U S A (2000) 1.88
HIV-1 Tat: coping with negative elongation factors. Curr Opin Immunol (1999) 1.81
Identification of a cyclin subunit required for the function of Drosophila P-TEFb. J Biol Chem (1998) 1.77
Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther (1997) 1.71
Intracellular trafficking and interactions of the HIV-1 Tat protein. Virology (1998) 1.57
Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol (1991) 1.34
Localization to the nucleolus is a common feature of coronavirus nucleoproteins, and the protein may disrupt host cell division. J Virol (2001) 1.32
Adenovirus core protein V is delivered by the invading virus to the nucleus of the infected cell and later in infection is associated with nucleoli. J Gen Virol (1998) 1.29
Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci U S A (1993) 1.29
A critical role for the TAR element in promoting efficient human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 1.22
Protein B23 is an important human factor for the nucleolar localization of the human immunodeficiency virus protein Tat. J Virol (1997) 1.16
Visualization of in vivo direct interaction between HIV-1 TAT and human cyclin T1 in specific subcellular compartments by fluorescence resonance energy transfer. J Biol Chem (2001) 1.10
The nucleolus is the site of Borna disease virus RNA transcription and replication. J Virol (1998) 1.04
Localization of human immunodeficiency virus Rev in transfected and virus-infected cells. AIDS Res Hum Retroviruses (1995) 1.00
Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Ther (1995) 0.97
The Rev protein is able to transport to the cytoplasm small nucleolar RNAs containing a Rev binding element. RNA (1999) 0.96
Nucleolar localization of the UL3 protein of herpes simplex virus type 2. J Gen Virol (1999) 0.92
Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy. J Virol (1999) 0.85
Posttranscriptional regulation by Rev protein of human immunodeficiency virus type 1 results in nonrandom nuclear localization of gag mRNA. Virology (1997) 0.84
Ultrastructural localization of the RNA of immunodeficiency viruses using electron microscopy in situ hybridization and in vitroinfected lymphocytes. Micron (2001) 0.84
Detection of SIV antigens by HIV-1 antigen capture immunoassays. J Acquir Immune Defic Syndr (1990) 0.83
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
Unlocking the potential of the human genome with RNA interference. Nature (2004) 6.70
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40
Strategies for silencing human disease using RNA interference. Nat Rev Genet (2007) 5.19
Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol (2006) 4.93
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92
Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res (2007) 4.91
MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A (2008) 4.16
TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol (2009) 4.05
Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol (2004) 3.85
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA (2005) 3.14
RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
MicroRNAs in disease and potential therapeutic applications. Mol Ther (2007) 2.73
Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res (2007) 2.62
Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol (2003) 2.48
Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17
SNPs in human miRNA genes affect biogenesis and function. RNA (2009) 2.08
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02
An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med (2011) 1.93
Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther (2002) 1.85
Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther (2003) 1.82
RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol (2010) 1.80
Localized expression of small RNA inhibitors in human cells. Mol Ther (2003) 1.78
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res (2007) 1.75
Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc (2006) 1.74
Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. Mol Ther (2005) 1.67
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res (2009) 1.64
Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem (2005) 1.64
Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells. Mol Ther (2007) 1.63
siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res (2005) 1.60
RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59
Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett (2005) 1.58
Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther (2013) 1.49
Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol (2006) 1.44
Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem (2010) 1.42
Functional siRNA expression from transfected PCR products. RNA (2002) 1.42
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
Lack of association of cytomegalovirus with human brain tumors. Mod Pathol (2005) 1.40
De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med (2012) 1.40
CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs. Proc Natl Acad Sci U S A (2009) 1.38
HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence. Nucleic Acids Res (2005) 1.37
Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res (2011) 1.36
Sequence context outside the target region influences the effectiveness of miR-223 target sites in the RhoB 3'UTR. Nucleic Acids Res (2009) 1.35
Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat Biotechnol (2004) 1.34
A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon. Nucleic Acids Res (2005) 1.34
A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha. Mol Ther (2007) 1.34
Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr (2013) 1.34
Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J (2007) 1.31
Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol Ther (2003) 1.29
RNAi and the P-body connection. Nat Cell Biol (2005) 1.29
Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes. Proc Natl Acad Sci U S A (2011) 1.28
TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood (2013) 1.27
A role for the Dicer helicase domain in the processing of thermodynamically unstable hairpin RNAs. Nucleic Acids Res (2008) 1.25
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) (2013) 1.21
Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther (2005) 1.21
Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol (2003) 1.20
Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One (2009) 1.19
Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides (2008) 1.17
A boost for the emerging field of RNA nanotechnology. ACS Nano (2011) 1.17
Aptamer-targeted cell-specific RNA interference. Silence (2010) 1.17
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther (2011) 1.16
Expressing short hairpin RNAs in vivo. Nat Methods (2006) 1.14
Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood (2009) 1.14
Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biol Blood Marrow Transplant (2012) 1.13
Current progress of RNA aptamer-based therapeutics. Front Genet (2012) 1.12
A role for human Dicer in pre-RISC loading of siRNAs. Nucleic Acids Res (2010) 1.11
Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides (2010) 1.10
Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther (2012) 1.10
Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol Ther (2003) 1.10
Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. Mol Ther (2007) 1.08
In vivo evidence insufficient to conclude that "KIR/HLA incompatibility between sexual partners confers protection against HIV-1 transmission". Blood (2013) 1.08
Small nuclear RNAs encoded by Herpesvirus saimiri upregulate the expression of genes linked to T cell activation in virally transformed T cells. Curr Biol (2005) 1.07
Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein. J Virol (2006) 1.07
Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J Control Release (2013) 1.07
Donor killer immunoglobulin-like receptor genes and reactivation of cytomegalovirus after HLA-matched hematopoietic stem-cell transplantation: HLA-C allotype is an essential cofactor. Front Immunol (2013) 1.06
Control of HIV-1 replication by RNA interference. Virus Res (2004) 1.05
Amplification of RNAi--targeting HLA mRNAs. Mol Ther (2005) 1.05
Coupling of RNAi-mediated target downregulation with gene replacement. Antisense Nucleic Acid Drug Dev (2003) 1.04
Uncoupling of RNAi from active translation in mammalian cells. RNA (2004) 1.04
Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS One (2012) 1.04
RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci (2003) 1.03
Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis (2012) 1.03
Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol Biol (2005) 1.03